Clinical Implications of DNA Analysis on ADPKD
This trial is active, not recruiting.
|Condition||autosomal dominant polycystic kidney disease|
|Collaborator||Otsuka Pharmaceutical Co., Ltd.|
|Start date||January 2014|
|End date||December 2016|
|Trial size||80 participants|
|Trial identifier||NCT02322385, Kyorin-PKD-1|
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disease. We plan DNA analysis using the next generation sequencer (NGS) and examine the relationship between mutational types and clinical phenotypes. The accuracy of DNA analysis with NGS is tested by Sanger's method. The kidney and life survival curves will be compared between PKD1, PKD2 and non-ADPKD family members.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
The relationship between mutational types and phenotypes
time frame: Depends on the observational period at least more than one year.
Identify the efficacy of next generation sequencing method
time frame: One year.
Male or female participants from 20 years up to 80 years old.
Inclusion Criteria: - The unrelated patients with ADPKD. Exclusion Criteria: - The patients whose clinical data are not compiled.
|Official title||Mutational Types and Phenotypes Relationship in Autosomal Dominant Polycystic Kidney Disease|
|Description||80 unrelated patients with ADPKD attending to the Kyorin University Hospital whose clinical data are compiled. DNA analysis is performed at Otsuka Pharmaceutical Laboratory. Clinical data include total kidney volume (TKV), TKV slope, eGFR, eGFR slope and other clinically relevant data.|
Call for more information